Oslo, Norway 11 April 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular mRNA technology for next generation nucleic acid medicine, today announces that its subsidiary Circio AB has entered a research evaluation agreement with Lonza, one of the world’s largest contract development and manufacturing organizations.
The research license enables Circio to test the circVec circular mRNA expression technology in Lonza’s proprietary transient expression system for protein production. Further updates will follow as necessary as the project progresses.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter – Hunter PR
Phone:+44 7821 255568
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.